BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 29290258)

  • 1. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Isaka M; Kojima H; Takahashi S; Omae K; Ohde Y
    Lung Cancer; 2018 Jan; 115():28-33. PubMed ID: 29290258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.
    Riquet M; Assouad J; Bagan P; Foucault C; Le Pimpec Barthes F; Dujon A; Danel C
    Ann Thorac Surg; 2005 Jan; 79(1):225-33. PubMed ID: 15620948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
    Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
    Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
    Sawyer TE; Bonner JA; Gould PM; Foote RL; Deschamps C; Trastek VF; Pairolero PC; Allen MS; Shaw EG; Marks RS; Frytak S; Lange CM; Li H
    Cancer; 1997 Oct; 80(8):1399-408. PubMed ID: 9338463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division.
    Shien K; Toyooka S; Soh J; Okami J; Higashiyama M; Kadota Y; Maeda H; Hayama M; Chida M; Funaki S; Okumura M; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):791-6. PubMed ID: 25805399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.
    Razi SS; Nguyen D; Villamizar N
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2469-2483.e4. PubMed ID: 31928821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
    Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
    Liu K; Chen HL; You QS; Huang JF; Wang H
    Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of metastatic N1 lymph nodes in completely resected non-small-cell lung cancer.
    Park S; Cho S; Yum SW; Kim K; Jheon S
    Interact Cardiovasc Thorac Surg; 2015 Nov; 21(5):624-9. PubMed ID: 26242319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival.
    Varlotto JM; Yao AN; DeCamp MM; Ramakrishna S; Recht A; Flickinger J; Andrei A; Reed MF; Toth JW; Fizgerald TJ; Higgins K; Zheng X; Shelkey J; Medford-Davis LN; Belani C; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):765-73. PubMed ID: 25752390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis].
    Huang GJ; Fang DK; Cheng GY; Zhang DC
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):62-4. PubMed ID: 16737625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer.
    Dai Y; Su XD; Long H; Lin P; Fu JH; Zhang LJ; Wang X; Wen ZS; Zhu ZH; Zhang X; Rong TH
    Chin J Cancer; 2010 May; 29(5):538-44. PubMed ID: 20426905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer.
    Lardinois D; Suter H; Hakki H; Rousson V; Betticher D; Ris HB
    Ann Thorac Surg; 2005 Jul; 80(1):268-74; discussion 274-5. PubMed ID: 15975380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonectomy vs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival?
    Luzzi L; Voltolini L; Campione A; Paladini P; Ghiribelli C; Di Bisceglie M; Gotti G
    J Cardiovasc Surg (Torino); 2003 Feb; 44(1):119-23. PubMed ID: 12627083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.
    Darling GE; Allen MS; Decker PA; Ballman K; Malthaner RA; Inculet RI; Jones DR; McKenna RJ; Landreneau RJ; Rusch VW; Putnam JB
    J Thorac Cardiovasc Surg; 2011 Mar; 141(3):662-70. PubMed ID: 21335122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.